Stock Detail
AVANIR PHARMACEUTICALS INC - CLASS A
Drug Manufacturers Other
AVNR @ Yahoo Finance | AVNR Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $2.60 | $2.63 | $-0.07 | -2.62% | 0.00 | $2.67 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $2.63 | $2.54 | 1.48M | 322.88M | 1.61M | -5.65 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 2.68 | 2.64 | 2.59 | 2.55 | 2.50 |
Stock Profile
Avanir Pharmaceuticals, a pharmaceutical company, focuses on developing, acquiring, and commercializing therapeutic products for the treatment of chronic diseases. Its products and product candidates address therapeutic markets, including the central nervous system, inflammation, and infectious diseases. The company's lead product candidate Zenvia is being developed for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder. Zenvia also completed Phase III clinical trial in patients with diabetic peripheral neuropathic (DPN) pain. Avanir's infectious disease drug candidate, AVP-21D9 is a human monoclonal antibody that is in pre-clinical development for the treatment of anthrax. The company has also licensed a compound to Novartis International Pharmaceutical, Ltd. for the treatment of inflammatory disease. In addition, the company's commercialized product, Abreva is an over-the-counter product for the treatment of cold sores and is marketed in North America by GlaxoSmithKline Consumer Healthcare. Further, it is using its Xenerex technology to develop human monoclonal antibodies for use as prophylactic and therapeutic drugs to prevent and treat anthrax and other infectious diseases. The company was founded in 1988 and is headquartered in Aliso Viejo, California.